Literature DB >> 17637762

Endocrine and immune responses to resistance training in prostate cancer patients.

D A Galvão1, K Nosaka, D R Taaffe, J Peake, N Spry, K Suzuki, K Yamaya, M R McGuigan, L J Kristjanson, R U Newton.   

Abstract

This study examined the effect of 20 weeks resistance training on a range of serum hormones and inflammatory markers at rest, and following acute bouts of exercise in prostate cancer patients undergoing androgen deprivation. Ten patients exercised twice weekly at high intensity for several upper and lower-body muscle groups. Neither testosterone nor prostate-specific antigen changed at rest or following an acute bout of exercise. However, serum growth hormone (GH), dehydroepiandrosterone (DHEA), interleukin-6, tumor necrosis factor-alpha and differential blood leukocyte counts increased (P < 0.05) following acute exercise. Resistance exercise does not appear to compromise testosterone suppression, and acute elevations in serum GH and DHEA may partly underlie improvements observed in physical function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637762     DOI: 10.1038/sj.pcan.4500991

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  30 in total

1.  Effects of resistance exercise and protein ingestion on blood leukocytes and platelets in young and older men.

Authors:  Juha J Hulmi; T Myllymäki; M Tenhumäki; N Mutanen; R Puurtinen; G Paulsen; A A Mero
Journal:  Eur J Appl Physiol       Date:  2010-01-26       Impact factor: 3.078

Review 2.  The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.

Authors:  T Hasenoehrl; M Keilani; T Sedghi Komanadj; M Mickel; M Margreiter; M Marhold; R Crevenna
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

3.  The effects of human sera conditioned by high-intensity exercise sessions and training on the tumorigenic potential of cancer cells.

Authors:  G Baldelli; M De Santi; M Gervasi; G Annibalini; D Sisti; P Højman; P Sestili; V Stocchi; E Barbieri; G Brandi
Journal:  Clin Transl Oncol       Date:  2020-05-23       Impact factor: 3.405

4.  Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy.

Authors:  Nicolas H Hart; Robert U Newton; Nigel A Spry; Dennis R Taaffe; Suzanne K Chambers; Kynan T Feeney; David J Joseph; Andrew D Redfern; Tom Ferguson; Daniel A Galvão
Journal:  BMJ Open       Date:  2017-05-30       Impact factor: 2.692

5.  A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.

Authors:  Robert U Newton; Dennis R Taaffe; Nigel Spry; Robert A Gardiner; Gregory Levin; Bradley Wall; David Joseph; Suzanne K Chambers; Daniel A Galvão
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

Review 6.  Exercise in prevention and management of cancer.

Authors:  Robert U Newton; Daniel A Galvão
Journal:  Curr Treat Options Oncol       Date:  2008-08-13

Review 7.  The Independent Effects of Strength Training in Cancer Survivors: a Systematic Review.

Authors:  Erik D Hanson; Chad W Wagoner; Travis Anderson; Claudio L Battaglini
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

Review 8.  Cancer, physical activity, and exercise.

Authors:  Justin C Brown; Kerri Winters-Stone; Augustine Lee; Kathryn H Schmitz
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

Review 9.  The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.

Authors:  Peter Busch Østergren; Caroline Kistorp; Finn Noe Bennedbæk; Jens Faber; Jens Sønksen; Mikkel Fode
Journal:  Nat Rev Urol       Date:  2016-04-26       Impact factor: 14.432

10.  A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.

Authors:  Daniel A Galvão; Nigel Spry; Dennis R Taaffe; James Denham; David Joseph; David S Lamb; Greg Levin; Gillian Duchesne; Robert U Newton
Journal:  BMC Cancer       Date:  2009-12-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.